Chemomab Therapeutics Ltd. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2019 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Chemomab Therapeutics Ltd. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2019 to Q2 2024.
  • Chemomab Therapeutics Ltd. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$3.63M, a 54.4% increase year-over-year.
  • Chemomab Therapeutics Ltd. annual Net Income (Loss) Attributable to Parent for 2023 was -$24.2M, a 12.4% increase from 2022.
  • Chemomab Therapeutics Ltd. annual Net Income (Loss) Attributable to Parent for 2022 was -$27.6M, a 122% decline from 2021.
  • Chemomab Therapeutics Ltd. annual Net Income (Loss) Attributable to Parent for 2021 was -$12.5M, a 110% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$3.63M +$4.34M +54.4% Apr 1, 2024 Jun 30, 2024 6-K 2024-08-21
Q1 2024 -$3.87M +$4.89M +55.8% Jan 1, 2024 Mar 31, 2024 6-K 2024-08-21
Q2 2023 -$33.1M -$7.97M -$1.78M -28.8% Apr 1, 2023 Jun 30, 2023 6-K 2024-08-21
Q1 2023 -$31.3M -$8.75M -$3.65M -71.5% Jan 1, 2023 Mar 31, 2023 6-K 2024-08-21
Q4 2022 -$27.6M -$8.27M -$3.24M -64.3% Oct 1, 2022 Dec 31, 2022 20-F 2024-03-28
Q3 2022 -$24.4M -$8.08M -$5.11M -172% Jul 1, 2022 Sep 30, 2022 10-Q 2022-11-10
Q2 2022 -$19.3M -$6.19M -$3.42M -123% Apr 1, 2022 Jun 30, 2022 6-K 2023-08-14
Q1 2022 -$15.9M -$5.1M -$3.4M -200% Jan 1, 2022 Mar 31, 2022 6-K 2023-08-14
Q4 2021 -$12.5M -$5.04M -$3.09M -158% Oct 1, 2021 Dec 31, 2021 20-F 2024-03-28
Q3 2021 -$9.39M -$2.97M -$1.74M -142% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$7.65M -$2.77M -$1.69M -156% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-10
Q1 2021 -$5.96M -$1.7M -$9K -0.53% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-10
Q4 2020 -$5.95M -$1.95M +$3.65M +65.2% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-30
Q3 2020 -$9.6M -$1.22M +$5.94M +82.9% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 -$15.5M -$1.08M +$3.36M +75.6% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-12
Q1 2020 -$18.9M -$1.7M +$8.22M +82.9% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-12
Q4 2019 -$27.1M -$5.6M Oct 1, 2019 Dec 31, 2019 10-K 2021-03-09
Q3 2019 -$7.17M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-16
Q2 2019 -$4.44M Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-14
Q1 2019 -$9.91M Jan 1, 2019 Mar 31, 2019 10-Q 2020-08-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.